Cybin
Cybin is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics for mental health conditions, including major depressive disorder and generalized anxiety disorder.
Services
Cybin is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics aimed at addressing mental health conditions. Key services include the development and facilitation of clinical trials for new therapeutic compounds, specifically targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD). Their services also extend to the training of clinicians through their EMBARK model, which supports the therapeutic use of psychedelics in clinical settings.
Products
Cybin is developing several proprietary compounds, including CYB003 and CYB004. CYB003 is a deuterated psilocybin analog aimed at treating major depressive disorder (MDD) and has received FDA Breakthrough Therapy Designation. Positive Phase 2 interim data showed rapid and significant improvements in depression symptoms after a single dose. CYB004 is a deuterated dimethyltryptamine (dDMT) molecule for treating generalized anxiety disorder (GAD), demonstrating improved bioavailability and pharmacokinetics in preclinical studies.
Research and Development
Cybin's research and development efforts focus on advancing psychedelic-based therapies. CYB003 has completed dosing in its Phase 2 study for MDD, with topline efficacy data expected in Q4 2023. The company is preparing for a potential Phase 3 study of CYB003 in early 2024. CYB004 has shown promising preclinical results, with improved bioavailability and pharmacokinetics. Cybin has conducted over 250 pre-clinical studies and holds more than 50 granted or pending patent applications.
Clinical Trials
Cybin is actively involved in managing and conducting clinical trials for its therapeutic compounds. Partnering with Worldwide Clinical Trials, Cybin oversees trials for mental health conditions like MDD. CYB003, which targets major depressive disorder, has shown positive results in Phase 2 with plans for Phase 3 in early 2024. CYB004 is being developed for generalized anxiety disorder, with preclinical studies showing improved bioavailability and pharmacokinetics.
Global Operations
Cybin operates globally, with a presence in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The company's international footprint enables it to conduct comprehensive research and clinical trials, leveraging diverse regulatory environments and healthcare systems. This global reach supports Cybin's mission to develop and deliver innovative psychedelic-based therapeutics across various markets.